Strs Ohio Buys 9,000 Shares of Mirum Pharmaceuticals, Inc. $MIRM

Strs Ohio lifted its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 243.2% in the 3rd quarter, HoldingsChannel reports. The fund owned 12,700 shares of the company’s stock after purchasing an additional 9,000 shares during the quarter. Strs Ohio’s holdings in Mirum Pharmaceuticals were worth $931,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Emerald Mutual Fund Advisers Trust boosted its holdings in shares of Mirum Pharmaceuticals by 0.7% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 219,038 shares of the company’s stock valued at $16,058,000 after buying an additional 1,496 shares in the last quarter. Emerald Advisers LLC lifted its holdings in shares of Mirum Pharmaceuticals by 20.9% during the 3rd quarter. Emerald Advisers LLC now owns 369,600 shares of the company’s stock valued at $27,095,000 after purchasing an additional 63,834 shares during the last quarter. Wolverine Asset Management LLC acquired a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter worth $782,000. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter worth $1,728,000. Finally, Concurrent Investment Advisors LLC purchased a new position in Mirum Pharmaceuticals during the 3rd quarter worth $220,000.

Insider Buying and Selling

In related news, Director Patrick J. Heron acquired 131,425 shares of the stock in a transaction on Friday, January 23rd. The shares were acquired at an average price of $68.48 per share, for a total transaction of $8,999,984.00. Following the transaction, the director owned 459,010 shares in the company, valued at approximately $31,433,004.80. This trade represents a 40.12% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Eric Bjerkholt sold 1,421 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $93.33, for a total transaction of $132,621.93. Following the sale, the chief financial officer directly owned 42,127 shares in the company, valued at $3,931,712.91. The trade was a 3.26% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 32,429 shares of company stock valued at $3,039,396 in the last three months. 22.87% of the stock is currently owned by company insiders.

Mirum Pharmaceuticals Trading Up 1.6%

NASDAQ MIRM opened at $100.85 on Thursday. Mirum Pharmaceuticals, Inc. has a 1 year low of $36.88 and a 1 year high of $101.50. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16. The company has a market capitalization of $5.18 billion, a PE ratio of -117.27 and a beta of 0.48. The company has a fifty day moving average of $78.97 and a 200 day moving average of $71.75.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.15. The business had revenue of $133.01 million during the quarter, compared to analyst estimates of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The company’s revenue was up 47.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.30) EPS. Research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Wall Street Zen upgraded Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a report on Thursday, January 22nd. Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Friday, December 19th. Evercore ISI reissued an “outperform” rating and issued a $101.00 target price on shares of Mirum Pharmaceuticals in a research report on Tuesday, January 20th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $130.00 price target on shares of Mirum Pharmaceuticals in a research report on Monday, December 8th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $104.92.

Key Stories Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Director Patrick J. Heron bought 131,425 shares at $68.48 (~$9.0M), increasing his stake ~40% — a strong insider vote of confidence that typically supports share demand. Heron Form 4
• Positive Sentiment: HC Wainwright reiterated a Buy and raised its price target (reported lift to $130) while publishing bullish long?term EPS projections (notably aggressive FY2030 and FY2029 estimates), which supports higher valuation expectations and likely attracted momentum buyers. Analyst Upgrade / 52?Week High
• Positive Sentiment: Mirum completed its acquisition of Bluejay Therapeutics, expanding its rare?disease pipeline and potential future revenue streams — a strategic corporate development investors view as accretive. Acquisition Announcement
• Neutral Sentiment: HC Wainwright adjusted near?term EPS forecasts (cut FY2027 and trimmed FY2028 modestly) while raising longer?range estimates — mixed guidance that tempers but does not negate the bullish long?term thesis. HC Wainwright Estimates
• Negative Sentiment: Several senior executives sold stock on Jan 26 at about $96.19: CEO Christopher Peetz (6,831 shares, ?$657K), COO Peter Radovich (3,143 shares), CFO Eric Bjerkholt (1,053 shares), and SVP Jolanda Howe (842 shares). Multiple insider sales on the same day can raise near?term investor caution about insider liquidity needs despite the large director buy. CEO Form 4 COO Form 4 CFO Form 4 SVP Form 4

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.